Evaluation of antibacterial activities of colistin, rifampicin and meropenem combinations against NDM-1-producing Klebsiella pneumoniae in 24 h in vitro time-kill experiments

Journal of Antimicrobial Chemotherapy

Volumn 71, Issue 8, 2016, Pages 2321-2325

  Lagerback P ^a   Khine, W W T ^a   Giske, C G ^b   Tangden T ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

COLISTIN; EXTENDED SPECTRUM BETA LACTAMASE; MEROPENEM; RIFAMPICIN; ANTIINFECTIVE AGENT; BETA LACTAMASE; BETA-LACTAMASE NDM-1; THIENAMYCIN DERIVATIVE;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; BACTERIUM ISOLATE; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; MGRB GENE; NONHUMAN; PMRB GENE; DNA SEQUENCE; DRUG EFFECTS; DRUG INTERACTION; ENZYMOLOGY; GENETICS; HUMAN; MICROBIAL SENSITIVITY TEST; MICROBIAL VIABILITY; SECRETION (PROCESS);

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; COLISTIN; DRUG INTERACTIONS; DRUG RESISTANCE, BACTERIAL; GENES, BACTERIAL; HUMANS; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; RIFAMPIN; SEQUENCE ANALYSIS, DNA; THIENAMYCINS;

EID: 84982221115     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkw213     Document Type: Article

References (20)

1. Tzouvelekis LS, Markogiannakis A, Psichogiou M et al. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev 2012; 25: 682-707.
2. Nordmann P, Poirel L. The difficult-to-control spread of carbapenemase producers among Enterobacteriaceae worldwide. Clin Microbiol Infect 2014; 20: 821-30.
3. Qureshi ZA, Paterson DL, Potoski BA et al. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother 2012; 56: 2108-13.
4. Tumbarello M, Viale P, Viscoli C et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemaseproducing K. pneumoniae: importance of combination therapy. Clin Infect Dis 2012; 55: 943-50.
5. Daikos GL, Tsaousi S, Tzouvelekis LS et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother 2014; 58: 2322-8.
6. Tamma PD, Cosgrove SE, Maragakis LL. Combination therapy for treatment of infections with Gram-negative bacteria. Clin Microbiol Rev 2012; 25: 450-70.
7. Paul M, Lador A, Grozinsky-Glasberg S et al. Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database Syst Rev 2014; issue 1: CD003344.
8. Giske CG, Fröding I, Hasan CM et al. Diverse sequence types of Klebsiella pneumoniae contribute to the dissemination of blaNDM-1 in India, Sweden, and the United Kingdom. Antimicrob Agents Chemother 2012; 56: 2735-8.
9. EUCAST. Clinical Breakpoints. http://www.eucast.org/clinical_breakpoints.
10. Cuzon G, Naas T, Bogaerts P et al. Evaluation of a DNA microarray for the rapid detection of extended-spectrum β-lactamases (TEM, SHV and CTX-M), plasmid-mediated cephalosporinases (CMY-2-like, DHA, FOX, ACC-1, ACT/MIR and CMY-1-like/MOX) and carbapenemases (KPC, OXA-48, VIM, IMP and NDM). J Antimicrob Chemother 2012; 67: 1865-9.
11. Garonzik SM, Li J, Thamlikitkul V et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 2011; 55: 3284-94.
12. Conte JE, Golden JA, Kelley MG et al. Intrapulmonary pharmacokinetics and pharmacodynamics of meropenem. Int J Antimicrob Agents 2005; 26: 449-56.
13. Sanofi. Rifampin, prescribing information. http://www.sanofi.us.
14. Cannatelli A, D'Andrea MM, Giani T et al. In vivo emergence of colistin resistance in Klebsiella pneumoniae producing KPC-type carbapenemases mediated by insertional inactivation of the PhoQ/PhoP mgrB regulator. Antimicrob Agents Chemother 2013; 57: 5521-6.
15. Jayol A, Poirel L, Brink A et al. Resistance to colistin associated with a single amino acid change in protein PmrB among Klebsiella pneumoniae isolates of worldwide origin. Antimicrob Agents Chemother 2014; 58: 4762-6.
16. Cannatelli A, Giani T, D'Andrea MM et al. MgrB inactivation is a common mechanism of colistin resistance in KPC-producing Klebsiella pneumoniae of clinical origin. Antimicrob Agents Chemother 2014; 58: 5696-703.
17. Tascini C, Tagliaferri E, Giani T et al. Synergistic activity of colistin plus rifampin against colistin-resistant KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 2013; 57: 3990-3.
18. Fernandez L, Breidenstein EB, Hancock RE. Creeping baselines and adaptive resistance to antibiotics. Drug Resist Updat 2011; 14: 1-21.
19. Bergen PJ, Forrest A, Bulitta JB et al. Clinically relevant plasma concentrations of colistin in combination with imipenem enhance pharmacodynamic activity against multidrug-resistant Pseudomonas aeruginosa at multiple inocula. Antimicrob Agents Chemother 2011; 55: 5134-42.
20. Cannatelli A, Santos-Lopez A, Giani T et al. Polymyxin resistance caused by mgrB inactivation is not associated with significant biological cost in Klebsiella pneumoniae. Antimicrob Agents Chemother 2015; 59: 2898-900.